Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib in Adult Participants With Moderate to Severe Crohn's Disease (CD) in Real World Clinical Practice.

Inclusion Criteria:

• A diagnosis of moderate-to-severe crohn's disease (CD).

• Participants initiating upadacitinib at the clinician's discretion as part of theirroutine clinical care; the decision to administer upadacitinib must be made prior toand independent of recruitment into the study.

• Participants prescribed upadacitinib in accordance with the approved local label.

• Able to understand and communicate with the investigator and comply with therequirements of the study.

• Willing to continue with study documentation after cessation of upadacitinib.

• Willing and able to participate in the collection of PRO data via a cloud-basedapplication on their personal or provided mobile phone or website app.

Exclusion Criteria:

• Any contraindication to upadacitinib.

• Previously exposure to upadacitinib in a clinical trial.

• Currently participating in interventional research (not including non-interventionalstudy, post-marketing observational study (PMOS) , or registry participation).

• Initiation of upadacitinib prior to enrollment.